Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436557 | 0.86 | MEN1 (0.46) | KMT2AALDH1A1OPRK1MEN1POLB | |
| SCHEMBL3435704 | 0.85 | ALDH1A1 (0.42) | KMT2AALDH1A1OPRK1MEN1SMN1; SMN2 | |
| SCHEMBL3436553 | 0.84 | SMN1; SMN2 (0.44) | KMT2AALDH1A1OPRK1MEN1POLB | |
| SCHEMBL3436532 | 0.84 | CHRM1 (0.45) | KMT2AALDH1A1OPRK1MEN1POLB | |
| SCHEMBL3435067 | 0.80 | ALDH1A1 (0.45) | ALDH1A1OPRK1SMN1; SMN2HSP90AA1HSP90AB1 | |
| SCHEMBL13999797 | 0.77 | AOC3 (0.38) | KMT2AALDH1A1MEN1POLBSMN1; SMN2 | |
| SCHEMBL3436568 | 0.77 | AOC3 (0.38) | KMT2AALDH1A1MEN1POLBSMN1; SMN2 | |
| SCHEMBL3436563 | 0.77 | AOC3 (0.38) | KMT2AALDH1A1MEN1POLBSMN1; SMN2 | |
| SCHEMBL3558817 | 0.77 | ALDH1A1 (0.38) | KMT2AALDH1A1MEN1POLBSMN1; SMN2 | |
| SCHEMBL3434342 | 0.77 | MEN1 (0.40) | KMT2AALDH1A1OPRK1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | KMT2A 1707/4885ALDH1A1 975/4885OPRK1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.